Urovant Sciences Ltd

NASDAQ:UROV  
16.05
+0.01 (+0.06%)
Regulatory, Mergers / Acquisitions, Equity Financing / Related

Urovant Sciences Enters Into Definitive Agreement For Sumitovant Biopharma

Published: 11/12/2020 22:32 GMT
Urovant Sciences Ltd (UROV) - Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares.
Urovant Sciences Ltd - Urovant Sciences Shareholders to Receive $16.25 per Share in Cash.
Urovant Sciences Ltd - Continues to Expect FDA Action on Its New Drug Application Submission for Vibegron in U.S. by December 26, 2020.